T1	CHEM 291 306	inmumoduladores
#1	AnnotatorNotes T1	C1527392; Immunomodulators; Immunologic Factor · Pharmacologic Substance
T2	CHEM 58 71	antioxidantes
#2	AnnotatorNotes T2	C0003402; Antioxidants; Pharmacologic Substance
T3	DISO 138 157	esclerosis múltiple
#3	AnnotatorNotes T3	C0026769; Multiple Sclerosis; Disease or Syndrome
T4	PROC 1653 1677	isoprostanos 8-iso-PGF2α
T5	PROC 194 205	tratamiento
#4	AnnotatorNotes T5	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T6	DISO 212 231	esclerosis múltiple
#5	AnnotatorNotes T6	C0026769; Multiple Sclerosis; Disease or Syndrome
T7	PROC 1891 1905	suplementación
#6	AnnotatorNotes T7	C0242297; Dietary Supplementation; Therapeutic or Preventive Procedure
T8	PROC 278 286	terapias
#7	AnnotatorNotes T8	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T9	PROC 1607 1651	marcadores de estrés oxidativo e inflamación
T10	PROC 347 383	estudios de intervención nutricional
T11	PROC 433 456	tratamiento alternativo
#8	AnnotatorNotes T11	C0683466; alternative medical treatment; Therapeutic or Preventive Procedure
T12	DISO 492 502	enfermedad
#9	AnnotatorNotes T12	C0012634; Disease; Disease or Syndrome
T13	PROC 524 550	intervenciones en la dieta
#10	AnnotatorNotes T13	C0086153; Dietary Modification; Therapeutic or Preventive Procedure
T14	DISO 602 610	síntomas
#11	AnnotatorNotes T14	C1457887; Symptoms; Sign or Symptom
T15	PROC 1300 1331	marcadores del estrés oxidativo
T16	PROC 699 713	suplementación
#12	AnnotatorNotes T16	C0242297; Dietary Supplementation; Therapeutic or Preventive Procedure
T17	CHEM 717 730	antioxidantes
#13	AnnotatorNotes T17	C0003402; Antioxidants; Pharmacologic Substance
T18	Food 2078 2100	suplementos dietéticos
#14	AnnotatorNotes T18	C0242295; Dietary Supplements; Food
T19	PROC 858 913	estudio prospectivo aleatorizado controlado por placebo
#15	AnnotatorNotes T19	C0033522; Prospective Studies; Research Activity + C0206034; Clinical Trials, Randomized; Research Activity + C0599724; placebo controlled study; Research Activity · Intellectual Product
T20	PROC 1978 2008	marcadores de estrés oxidativo
T21	CHEM 1026 1038	antioxidante
#16	AnnotatorNotes T21	C0003402; Antioxidants; Pharmacologic Substance
T22	PROC 1067 1074	placebo
#17	AnnotatorNotes T22	C0032042; Placebos; Therapeutic or Preventive Procedure
T23	PROC 1125 1147	intervención dietética
#18	AnnotatorNotes T23	C1883292; Therapeutic Dietary Intervention; Therapeutic or Preventive Procedure
T24	PROC 1241 1297	valoraciones de parámetros antropométricos y bioquímicos
T25	DISO 1315 1331	estrés oxidativo
#19	AnnotatorNotes T25	C0242606; Oxidative Stress; Cell or Molecular Dysfunction
T26	ANAT 1335 1341	sangre
#20	AnnotatorNotes T26	C0005767; Blood; Body Substance
T27	PROC 1422 1433	tratamiento
#21	AnnotatorNotes T27	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T28	PROC 1462 1492	niveles de proteína C reactiva
#22	AnnotatorNotes T28	C0201657; C-reactive protein measurement; Laboratory Procedure
T29	PROC 1573 1580	placebo
#23	AnnotatorNotes T29	C0032042; Placebos; Therapeutic or Preventive Procedure
T30	DISO 1621 1637	estrés oxidativo
#24	AnnotatorNotes T30	C0242606; Oxidative Stress; Cell or Molecular Dysfunction
T31	DISO 1640 1651	inflamación
#25	AnnotatorNotes T31	C0021368; Inflammation; Pathologic Function
T32	PROC 1680 1697	interleucina IL-6
#26	AnnotatorNotes T32	C0919829; Interleukin 6 Measurement; Laboratory Procedure
T33	PROC 1761 1783	intervención dietética
#27	AnnotatorNotes T33	C1883292; Therapeutic Dietary Intervention; Therapeutic or Preventive Procedure
T34	CHEM 1804 1819	enzima catalasa
T35	CHEM 1910 1923	antioxidantes
#28	AnnotatorNotes T35	C0003402; Antioxidants; Pharmacologic Substance
T36	DISO 1992 2008	estrés oxidativo
#29	AnnotatorNotes T36	C0242606; Oxidative Stress; Cell or Molecular Dysfunction
T37	DISO 2179 2190	inflamación
#30	AnnotatorNotes T37	C0021368; Inflammation; Pathologic Function
T38	CHEM 2251 2276	suplementos antioxidantes
T39	PROC 2305 2326	terapias alternativas
#31	AnnotatorNotes T39	C0683466; alternative medical treatment; Therapeutic or Preventive Procedure
T40	PROC 2333 2344	tratamiento
#32	AnnotatorNotes T40	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T41	PROC 15 35	dieta baja en grasas
#33	AnnotatorNotes T41	C0242970; Fat-Restricted Diet; Therapeutic or Preventive Procedure
T42	CHEM 29 35	grasas
#34	AnnotatorNotes T42	C0015677; Fatty acid glycerol esters; Organic Chemical · Pharmacologic Substance
T43	DISO 233 235	EM
#35	AnnotatorNotes T43	C0026769; Multiple Sclerosis; Disease or Syndrome
T44	DISO 339 341	EM
#36	AnnotatorNotes T44	C0026769; Multiple Sclerosis; Disease or Syndrome
T45	PROC 400 405	dieta
#37	AnnotatorNotes T45	C1519433; Special Diet Therapy; Therapeutic or Preventive Procedure
T46	DISO 632 634	EM
#38	AnnotatorNotes T46	C0026769; Multiple Sclerosis; Disease or Syndrome
T47	PROC 673 694	dieta pobre en grasas
#39	AnnotatorNotes T47	C0242970; Fat-Restricted Diet; Therapeutic or Preventive Procedure
T48	CHEM 688 694	grasas
#40	AnnotatorNotes T48	C0015677; Fatty acid glycerol esters; Organic Chemical · Pharmacologic Substance
T49	DISO 830 832	EM
#41	AnnotatorNotes T49	C0026769; Multiple Sclerosis; Disease or Syndrome
T50	PROC 974 986	intervención
#42	AnnotatorNotes T50	C0184661; Interventional procedure; Therapeutic or Preventive Procedure
T51	PROC 988 1008	dieta baja en grasas
#43	AnnotatorNotes T51	C0242970; Fat-Restricted Diet; Therapeutic or Preventive Procedure
T52	CHEM 1002 1008	grasas
#44	AnnotatorNotes T52	C0015677; Fatty acid glycerol esters; Organic Chemical · Pharmacologic Substance
T53	PROC 1011 1038	suplementación antioxidante
T54	PROC 1076 1096	dieta baja en grasas
#45	AnnotatorNotes T54	C0242970; Fat-Restricted Diet; Therapeutic or Preventive Procedure
T55	CHEM 1090 1096	grasas
#46	AnnotatorNotes T55	C0015677; Fatty acid glycerol esters; Organic Chemical · Pharmacologic Substance
T56	PROC 1159 1183	modificación de la dieta
#47	AnnotatorNotes T56	C0086153; Dietary Modification; Therapeutic or Preventive Procedure
T57	CHEM 1202 1215	antioxidantes
#48	AnnotatorNotes T57	C0003402; Antioxidants; Pharmacologic Substance
T58	ANAT 1344 1349	orina
#49	AnnotatorNotes T58	C0042036; Urine; Body Substance
T59	CHEM 1473 1492	proteína C reactiva
#50	AnnotatorNotes T59	C0006560; C-reactive protein; Amino Acid, Peptide, or Protein · Immunologic Factor
T60	PROC 1538 1550	intervención
#51	AnnotatorNotes T60	C0184661; Interventional procedure; Therapeutic or Preventive Procedure
T61	PROC 1734 1746	intervención
#52	AnnotatorNotes T61	C0184661; Interventional procedure; Therapeutic or Preventive Procedure
T62	PROC 1866 1878	intervención
#53	AnnotatorNotes T62	C0184661; Interventional procedure; Therapeutic or Preventive Procedure
T63	PROC 2066 2071	dieta
#54	AnnotatorNotes T63	C1519433; Special Diet Therapy; Therapeutic or Preventive Procedure
T64	ANAT 2153 2160	celular
#55	AnnotatorNotes T64	C0007634; Cells; Cell | C1269647; Entire cell; Cell
T65	DISO 2197 2199	EM
#56	AnnotatorNotes T65	C0026769; Multiple Sclerosis; Disease or Syndrome
T66	PROC 2222 2244	dietas bajas en grasas
#57	AnnotatorNotes T66	C0242970; Fat-Restricted Diet; Therapeutic or Preventive Procedure
T67	CHEM 2238 2244	grasas
#58	AnnotatorNotes T67	C0015677; Fatty acid glycerol esters; Organic Chemical · Pharmacologic Substance
T68	DISO 2351 2353	EM
#59	AnnotatorNotes T68	C0026769; Multiple Sclerosis; Disease or Syndrome
T69	PROC 40 54	suplementación
#60	AnnotatorNotes T69	C0242297; Dietary Supplementation; Therapeutic or Preventive Procedure
T73	Spec_cue 406 411	puede
T75	LIVB 618 627	pacientes
#61	AnnotatorNotes T75	C0030705; Patients; Patient or Disabled Group
T77	LIVB 764 793	pacientes institucionalizados
#62	AnnotatorNotes T77	C0030705; Patients; Patient or Disabled Group + C0376326; Institutionalized Persons; Patient or Disabled Group
T78	LIVB 965 986	grupo de intervención
#63	AnnotatorNotes T78	C2986530; Intervention Group; Population Group | C5205743; Experimental Group; Population Group
T79	Duration 1224 1231	42 días
T82	Date 1393 1399	día 15
T83	LIVB 1529 1550	grupo de intervención
#64	AnnotatorNotes T83	C2986530; Intervention Group; Population Group | C5205743; Experimental Group; Population Group
T84	LIVB 1725 1746	grupo de intervención
#65	AnnotatorNotes T84	C2986530; Intervention Group; Population Group | C5205743; Experimental Group; Population Group
T85	LIVB 1857 1878	grupo de intervención
#66	AnnotatorNotes T85	C2986530; Intervention Group; Population Group | C5205743; Experimental Group; Population Group
T88	PHYS 2141 2160	metabolismo celular
#67	AnnotatorNotes T88	C1524026; Metabolic Process, Cellular; Cell Function
T89	Spec_cue 2277 2284	podrían
T90	LIVB 105 133	residentes de larga estancia
#68	AnnotatorNotes T90	C3640869; Long-term Facility Resident; Patient or Disabled Group
T70	LIVB 920 933	participantes
#69	AnnotatorNotes T70	C4554048; Study Participant; Population Group
T71	Date 1373 1378	día 0
T72	Date 1410 1416	día 42
T74	Spec_cue 384 392	sugieren
T76	PROC 774 793	institucionalizados
#70	AnnotatorNotes T76	C0021629; Institutionalization; Health Care Activity
A1	Assertion T11 Speculated
A2	Assertion T39 Speculated
A3	Assertion T45 Speculated
A4	Assertion T38 Speculated
A5	Assertion T66 Speculated
T80	Neg_cue 1925 1927	No
T81	CONC 1942 1953	diferencias
A6	Assertion T81 Negated
#71	AnnotatorNotes T81	C1705241; Delta (difference); Quantitative Concept
R1	Negation Arg1:T80 Arg2:T81	
T86	Neg_cue 321 323	no
T87	Quantifier_or_Qualifier 324 335	progresivas
A7	Assertion T87 Negated
R2	Negation Arg1:T86 Arg2:T87	
R3	Has_Quantifier_or_Qualifier Arg1:T44 Arg2:T87	
R4	Speculation Arg1:T74 Arg2:T45	
R5	Speculation Arg1:T73 Arg2:T11	
R6	Speculation Arg1:T89 Arg2:T39	
T91	Spec_cue 551 557	pueden
T92	Observation 567 587	mejorar el bienestar
A8	Assertion T92 Speculated
R7	Speculation Arg1:T91 Arg2:T92	
T93	Observation 590 610	mejorar los síntomas
A9	Assertion T93 Speculated
R8	Speculation Arg1:T91 Arg2:T93	
#72	AnnotatorNotes T34	C0007367; catalase; Amino Acid, Peptide, or Protein · Enzyme
T94	Duration 119 133	larga estancia
T95	Observation 1 7	Efecto
#73	AnnotatorNotes T95	C1518681; Outcome of Therapy; Finding (?)
R9	Causes Arg1:T41 Arg2:T95	
R10	Used_for Arg1:T2 Arg2:T69	
R11	Experiences Arg1:T90 Arg2:T3	
R12	Experiences Arg1:T90 Arg2:T95	
R13	Experiences Arg1:T90 Arg2:T41	
T96	CONC 79 101	marcadores bioquímicos
#74	AnnotatorNotes T96	C0206015; Biochemical Marker; Qualitative Concept
R15	Used_for Arg1:T1 Arg2:T8	
R16	Used_for Arg1:T1 Arg2:T5	
T97	Observation 475 502	progresión de la enfermedad
#75	AnnotatorNotes T97	C1457868; Worse; Finding
R17	Before Arg1:T12 Arg2:T97	
R18	Experiences Arg1:T75 Arg2:T46	
R19	Experiences Arg1:T75 Arg2:T14	
R20	Experiences Arg1:T75 Arg2:T93	
R21	Experiences Arg1:T75 Arg2:T92	
R22	Experiences Arg1:T75 Arg2:T13	
T98	Observation 659 665	efecto
#76	AnnotatorNotes T98	C1518681; Outcome of Therapy; Finding (?)
R23	Causes Arg1:T47 Arg2:T98	
R24	Used_for Arg1:T17 Arg2:T16	
T99	CONC 738 760	marcadores bioquímicos
#77	AnnotatorNotes T99	C0206015; Biochemical Marker; Qualitative Concept
R25	Experiences Arg1:T77 Arg2:T76	
R26	Experiences Arg1:T77 Arg2:T47	
R27	Experiences Arg1:T77 Arg2:T98	
T100	Observation 808 826	formas progresivas
#78	AnnotatorNotes T100	C1457868; Worse; Finding
R28	Before Arg1:T49 Arg2:T100	
R29	Experiences Arg1:T77 Arg2:T100	
R30	Experiences Arg1:T77 Arg2:T49	
R31	Experiences Arg1:T78 Arg2:T50	
R32	Experiences Arg1:T78 Arg2:T51	
R33	Used_for Arg1:T21 Arg2:T53	
R34	Experiences Arg1:T70 Arg2:T22	
R35	Experiences Arg1:T70 Arg2:T54	
R36	Has_Duration_or_Interval Arg1:T57 Arg2:T79	
R37	Location_of Arg1:T26 Arg2:T15	
R38	Location_of Arg1:T58 Arg2:T15	
R39	Location_of Arg1:T26 Arg2:T25	
R40	Location_of Arg1:T58 Arg2:T25	
R41	Overlap Arg1:T15 Arg2:T71	
R42	Overlap Arg1:T15 Arg2:T82	
R43	Overlap Arg1:T15 Arg2:T72	
R44	Overlap Arg1:T27 Arg2:T72	
R45	Overlap Arg1:T27 Arg2:T82	
R46	Overlap Arg1:T27 Arg2:T71	
R47	Combined_with Arg1:T51 Arg2:T53	
R14	Combined_with Arg1:T41 Arg2:T69	
R48	Combined_with Arg1:T47 Arg2:T16	
R49	Combined_with Arg1:T56 Arg2:T57	
R50	Has_Duration_or_Interval Arg1:T23 Arg2:T79	
T101	Observation 1112 1118	efecto
#79	AnnotatorNotes T101	C1518681; Outcome of Therapy; Finding (?)
R51	Causes Arg1:T23 Arg2:T101	
R52	Causes Arg1:T56 Arg2:T101	
R53	Overlap Arg1:T24 Arg2:T71	
R54	Overlap Arg1:T24 Arg2:T82	
R55	Overlap Arg1:T24 Arg2:T72	
R56	Has_Duration_or_Interval Arg1:T27 Arg2:T79	
R57	Experiences Arg1:T83 Arg2:T60	
R58	Experiences Arg1:T83 Arg2:T28	
R63	Experiences Arg1:T84 Arg2:T61	
R64	Experiences Arg1:T85 Arg2:T62	
R65	Used_for Arg1:T35 Arg2:T7	
R66	Experiences Arg1:T85 Arg2:T7	
T102	Observation 1788 1827	actividad de la enzima catalasa aumentó
R67	Before Arg1:T102 Arg2:T7	
R68	Experiences Arg1:T85 Arg2:T102	
R71	After Arg1:T9 Arg2:T33	
R72	After Arg1:T4 Arg2:T33	
R73	After Arg1:T32 Arg2:T33	
T104	Spec_cue 2050 2058	sugieren
T105	Quantifier_or_Qualifier 2107 2119	involucrados
A10	Assertion T105 Speculated
R74	Speculation Arg1:T104 Arg2:T105	
R75	Location_of Arg1:T64 Arg2:T88	
R76	Combined_with Arg1:T63 Arg2:T18	
R77	Causes Arg1:T65 Arg2:T37	
R78	Speculation Arg1:T89 Arg2:T66	
R79	Speculation Arg1:T89 Arg2:T38	
R80	Combined_with Arg1:T66 Arg2:T38	
R81	Before Arg1:T13 Arg2:T92	
R82	Before Arg1:T13 Arg2:T93	
R83	Experiences Arg1:T70 Arg2:T50	
R84	Experiences Arg1:T70 Arg2:T51	
R87	Has_Quantifier_or_Qualifier Arg1:T63 Arg2:T105	
T106	Quantifier_or_Qualifier 1954 1968	significativas
A11	Assertion T106 Negated
#81	AnnotatorNotes T106	C0750502; Significant; Idea or Concept
R88	Has_Quantifier_or_Qualifier Arg1:T81 Arg2:T106	
R89	Negation Arg1:T80 Arg2:T106	
R69	Has_Quantifier_or_Qualifier Arg1:T6 Arg2:T87	
R70	Has_Quantifier_or_Qualifier Arg1:T43 Arg2:T87	
R90	Causes Arg1:T46 Arg2:T14	
T103	CONC 1584 1601	final del estudio
R59	Overlap Arg1:T28 Arg2:T103	
#80	AnnotatorNotes T103	C2983670; Study End Date; Temporal Concept
#82	AnnotatorNotes T87	C0205329; Progressive; Functional Concept
#83	AnnotatorNotes T105	C1314939; Involvement with; Functional Concept
A12	Experiencer T90 Patient
A13	Experiencer T75 Patient
A14	Experiencer T77 Patient
A15	Experiencer T70 Patient
A16	Experiencer T78 Patient
A17	Experiencer T83 Patient
A18	Experiencer T84 Patient
A19	Experiencer T85 Patient
